申请人:Janssen Pharmaceutica N.V.
公开号:US05629308A1
公开(公告)日:1997-05-13
Antiallergic imidazo[1,2-a](pyrrolo, thieno or furano)[2,3-d]azepines of formula ##STR1## the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein each of the dotted lines independently represents an optional bond; R.sup.1 represents hydrogen, C.sub.1-4 alkyl, halo, ethenyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, hydroxyC.sub.1-4 alkyl, formyl, hydroxycarbonyl or hydroxycarbonylC.sub.1-4 alkyl; R.sup.2 represents hydrogen, C.sub.1-4 alkyl, ethenyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, C.sub.1-4 alkyl substituted with hydroxycarbonyl or C.sub.1-4 alkyloxycarbonyl, hydroxyC.sub.1-4 alkyl, formyl or hydroxycarbonyl; R.sup.3 represents hydrogen, C.sub.1-4 alkyl, hydroxyC.sub.1-4 alkyl, phenyl or halo; X represents O, S or NR.sub.4 ; L represents hydrogen; C.sub.1-6 alkyl; substituted C.sub.1-6 alkyl; C.sub.3-6 alkenyl; C.sub.3-6 alkenyl substituted with aryl; or a radical of formula-Alk-Y-Het.sup.1 (a-1), --Alk-NH-CO-Het.sup.2 (a-2) or -Alk-Het.sup.3 (a-3). Compositions comprising said compounds, processes of preparing the same and intermediates in the preparation thereof.
抗过敏的咪唑[1,2-a](吡咯、噻吩或呋喃)[2,3-d]氮杂环庚烷的化学式为##STR1##,其药学上可接受的盐和立体化学异构体,其中每个虚线独立表示一个可选键;R.sup.1代表氢、C.sub.1-4烷基、卤素、乙烯基取代的羟基羰基或C.sub.1-4烷氧羰基、羟基C.sub.1-4烷基、甲酰基、羟基羰基或羟基羰基C.sub.1-4烷基;R.sup.2代表氢、C.sub.1-4烷基、乙烯基取代的羟基羰基或C.sub.1-4烷氧羰基、C.sub.1-4烷基取代的羟基羰基或C.sub.1-4烷氧羰基、羟基C.sub.1-4烷基、甲酰基或羟基羰基;R.sup.3代表氢、C.sub.1-4烷基、羟基C.sub.1-4烷基、苯基或卤素;X代表O、S或NR.sub.4;L代表氢;C.sub.1-6烷基;取代的C.sub.1-6烷基;C.sub.3-6烯基;取代芳基的C.sub.3-6烯基;或化学式-Alk-Y-Het.sup.1 (a-1)、--Alk-NH-CO-Het.sup.2 (a-2)或-Alk-Het.sup.3 (a-3)的基团。包含上述化合物的组合物,其制备方法及制备过程中的中间体。